Lenzing's Balance Sheet Gets Its Fix: The €300 Million Question Is What Comes Next

Lenzing's 28% fall was mostly the ex-rights adjustment, not a collapse. Berenberg cut the stock to Hold and its target to €17 from €29.50.

A 28% single-session drop in Lenzing's share price looks alarming on a screen. In this case, most of it was arithmetic. The Austrian fibre maker's stock closed Friday at €14.02, but that print reflects the first day of trading ex-subscription-right, not a sudden collapse in the company's underlying value. Once the mechanical adjustment is stripped out, what remains is a more nuanced picture: a balance sheet in the process of being repaired, and a market still unsure whether the repair goes deep enough.

The Rights Issue, by the Numbers

Lenzing has locked in the terms of a cash capital increase targeting gross proceeds of roughly €300 million. Existing shareholders may subscribe to 9 new shares for every 10 they hold, at a subscription price of €8.65 per share. That price sits at a 42.50% discount to the theoretical value ex-rights — a gap that says as much about the pressure behind the recapitalisation as it does about the offer's appeal.

The issuance covers 34,756,362 new no-par-value shares, lifting the company's share capital from €40,107,738.37 to €76,204,702.90. The transaction is fully underwritten: core shareholders B&C Group, Suzano, and Oberbank have committed in advance to exercise their subscription rights in full, which removes any doubt about whether the €300 million will land.

Trading in the subscription rights runs on the Vienna Stock Exchange from 6 to 14 October 2026. The subscription period itself opens Tuesday, 6 October, and closes on 20 October 2026. Investors who neither exercise nor sell their rights during that window should note that the rights expire worthless once the deadline passes. An international private placement of any unsubscribed new shares is scheduled for 20 October, with delivery and the start of trading in the new stock planned for 23 October 2026, contingent on the capital increase being entered in the commercial register by then.

Berenberg Pulls the Plug

The arithmetic alone does not explain the scale of Friday's move. Berenberg supplied the second half of the story, cutting its rating on Lenzing from "Buy" to "Hold" and slashing its price target from €29.50 to €17.00 — a revision of more than 40% in a single stroke.

The downgrade rests on a deteriorating earnings outlook. Berenberg now expects a markedly higher loss per share for the 2026 financial year than previously modelled, and media reports indicate the bank trimmed its 2026 EBITDA forecast to €55 million, citing looming pressure from raw material costs and restructuring charges. Higher viscose and cotton prices have provided some tailwind, but according to the analysts that relief has not flowed through to Lenzing's operating result the way the market had hoped.

The bank also flagged growing uncertainty about the shareholder structure going forward. While the core investors' commitment secures the transaction, Berenberg sees rising doubt over whether Suzano will extend its engagement beyond its existing rights.

A Chart That Tells Its Own Story

Friday's slide carried the stock to a new 52-week low of €13.68. Measured against the 52-week high of €29.75, the shares now sit 53% below their peak. That gap captures the depth of the confidence problem facing management: the capital raise plugs a funding hole and shores up the balance sheet, but it does nothing to address the operational issues Berenberg laid out so bluntly.

For shareholders weighing their options during the subscription window, the trade-off is clear. On one side sits a guaranteed liquidity injection, fully backstopped by the anchor investors through the 10-for-9 ratio. On the other sits a business that has yet to demonstrate it can convert rising fibre prices into meaningfully better margins and earnings. When that conversion fails to materialise, the problem runs deeper than liquidity — and the coming weeks of the subscription period are unlikely to offer much comfort as the stock searches for a floor after its double hit.